I 
115TH CONGRESS 
1ST SESSION H. R. 1660 
To direct the Administrator of the United States Agency for International 
Development to submit to Congress a report on the development and 
use of global health innovations in the programs, projects, and activities 
of the Agency. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 21, 2017 
Mr. SIRES (for himself, Mr. DIAZ-BALART, Mr. CONNOLLY, Mr. ENGEL, Mr. 
SHERMAN, Mr. CICILLINE, Mr. KEATING, Ms. ROS-LEHTINEN, Mr. 
DONOVAN, and Mr. SMITH of New Jersey) introduced the following bill; 
which was referred to the Committee on Foreign Affairs 
A BILL 
To direct the Administrator of the United States Agency 
for International Development to submit to Congress a 
report on the development and use of global health inno-
vations in the programs, projects, and activities of the 
Agency. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Global Health Innova-
tion Act of 2017’’. 
VerDate Sep 11 2014 
04:20 Mar 23, 2017
Jkt 069200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H1660.IH
H1660
lotter on DSK5VPTVN1PROD with BILLS
SEC. 2. ANNUAL REPORT. 
(a) IN GENERAL.—Not later than 180 days after the 
date of the enactment of this Act, and annually thereafter 
for a period of 4 years, the Administrator of the United 
States Agency for International Development shall submit 
to Congress a report on the development and use of global 
health innovations in the programs, projects, and activities 
of the Agency. 
(b) MATTERS TO BE INCLUDED.—The report re-
quired by subsection (a) shall include the following: 
(1) A description of— 
(A) the extent to which global health inno-
vations described in subsection (a) include 
drugs, diagnostics, devices, vaccines, electronic 
and mobile health technologies, and related be-
havior change and service delivery innovations; 
(B) how innovation has advanced the 
Agency’s commitments to achieving an HIV/ 
AIDS-free generation, ending preventable child 
and maternal deaths, and protecting commu-
nities from infectious diseases, as well as 
furthered by the Global Health Strategic 
Framework; 
(C) how goals are set for health product 
development in relation to the Agency’s health- 
VerDate Sep 11 2014 
04:20 Mar 23, 2017
Jkt 069200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H1660.IH
H1660
lotter on DSK5VPTVN1PROD with BILLS
related goals and how progress and impact are 
measured towards those goals; 
(D) how the Agency’s investments in inno-
vation relate to its stated goals; and 
(E) progress made towards health product 
development goals. 
(2) How the Agency, both independently and 
with partners, donors, and public-private partner-
ships, is— 
(A) leveraging United States investments 
to achieve greater impact in health innovation; 
(B) engaging in activities to develop, ad-
vance, and introduce affordable, available, and 
appropriate global health products; and 
(C) scaling up appropriate health innova-
tions in the development pipeline. 
(3) A description of collaboration and coordina-
tion with other Federal departments and agencies, 
including the Centers for Disease Control and Pre-
vention, in support of global health product develop-
ment, including a description of how the Agency is 
working to ensure critical gaps in product develop-
ment for global health are being filled. 
(4) A description of how the Agency is coordi-
nating and aligning global health innovation activi-
VerDate Sep 11 2014 
04:20 Mar 23, 2017
Jkt 069200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H1660.IH
H1660
lotter on DSK5VPTVN1PROD with BILLS
ties between the Global Development Lab, the Cen-
ter for Accelerating Innovation and Impact, and the 
Bureau for Global Health. 
Æ 
VerDate Sep 11 2014 
04:20 Mar 23, 2017
Jkt 069200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\H1660.IH
H1660
lotter on DSK5VPTVN1PROD with BILLS